1.Long Term Complete Response of Unresectable Locally Advanced Pancreatic Cancer after CCRT and Gemcitabine Chemotherapy.
Jaeyun YANG ; Taekyu LIM ; Taegyoon KIM ; Seungmoon HAN ; Sanghee LEE ; Huiseo KIM ; Jiwon LEE ; Seongyeong AHN
Korean Journal of Pancreas and Biliary Tract 2016;21(4):209-215
Locally advanced or metastatic disease accounts for two thirds of total patients with pancreatic cancer. Patients with pancreatic cancer are assessed as resectable, potentially resectable (borderline) or unresectable according to pre-operative examinations. The chances of resectability may be enhanced by using neoadjuvant systemic chemotherapy, radiotherapy or both. This case report presents a locally advanced pancreatic adenocarcinoma that was identified to be unresectable during surgical exploration. After receiving concurrent chemoradiotherapy, the patient was re-evaluated, identified as unresectable and received gemcitabine maintenance chemotherapy. Herein, we report the case of a patient with unresectable locally advanced pancreatic adenocarcinoma who achieved a complete response lasting for more than 32 months after receiving concurrent chmoradiotherapy followed by gemcitabine maintenance chemotherapy.
Adenocarcinoma
;
Chemoradiotherapy
;
Drug Therapy*
;
Humans
;
Maintenance Chemotherapy
;
Pancreatic Neoplasms*
;
Radiotherapy
2.Long Term Complete Response of Unresectable Locally Advanced Pancreatic Cancer after CCRT and Gemcitabine Chemotherapy.
Jaeyun YANG ; Taekyu LIM ; Taegyoon KIM ; Seungmoon HAN ; Sanghee LEE ; Huiseo KIM ; Jiwon LEE ; Seongyeong AHN
Korean Journal of Pancreas and Biliary Tract 2016;21(4):209-215
Locally advanced or metastatic disease accounts for two thirds of total patients with pancreatic cancer. Patients with pancreatic cancer are assessed as resectable, potentially resectable (borderline) or unresectable according to pre-operative examinations. The chances of resectability may be enhanced by using neoadjuvant systemic chemotherapy, radiotherapy or both. This case report presents a locally advanced pancreatic adenocarcinoma that was identified to be unresectable during surgical exploration. After receiving concurrent chemoradiotherapy, the patient was re-evaluated, identified as unresectable and received gemcitabine maintenance chemotherapy. Herein, we report the case of a patient with unresectable locally advanced pancreatic adenocarcinoma who achieved a complete response lasting for more than 32 months after receiving concurrent chmoradiotherapy followed by gemcitabine maintenance chemotherapy.
Adenocarcinoma
;
Chemoradiotherapy
;
Drug Therapy*
;
Humans
;
Maintenance Chemotherapy
;
Pancreatic Neoplasms*
;
Radiotherapy
3.Core signaling pathways and new therapeutic targets in pancreatic cancer.
Lei YOU ; Ge CHEN ; Yu-pei ZHAO
Chinese Medical Journal 2010;123(9):1210-1215
OBJECTIVEPancreatic cancer is a highly aggressive malignancy that has been resistant to treatment. Advances in cancer genetics have improved our understanding of this disease, but the genetics of pancreatic cancer remain poorly understood. A better understanding of the pathogenic role of specific gene mutations and core signaling pathways would propel the development of more effective treatments. The objective in this review was to highlight recent research that shows promise for new treatments for pancreatic cancer.
DATA SOURCESAll articles cited in this review were mainly searched from PubMed, which were published in English from 1993 to 2009.
STUDY SELECTIONOriginal articles and critical reviews selected were relevant to the molecular mechanisms of pancreatic cancer.
RESULTSDysregulation of core signaling pathways and processes through frequently genetic alterations can explain the major features of pancreatic tumorigenesis. New therapeutic targets based on recent research are emerging that hold promise for the future management of pancreatic cancer.
CONCLUSIONNew agents used in conjunction with standard radiotherapy and chemotherapy might help to overcome drug resistance by targeting multiple signaling pathways to induce responsiveness of pancreatic cancer cells to death signals.
Humans ; Pancreatic Neoplasms ; drug therapy ; metabolism ; radiotherapy ; Signal Transduction ; drug effects ; radiation effects
4.Relief of Cancer Pain in Patients with Pancreatic Cancer
The Korean Journal of Gastroenterology 2019;74(2):81-86
Pancreatic cancer is a dismal disease with a poor prognosis and is one of the most painful malignancies. Therefore, adequate pain control is essential to improving the patient's quality of life. Pain in pancreatic cancer has complex pathophysiologic mechanisms and different characteristics. The choice of pain management modalities should be individualized depending on the pain characteristics using a multidisciplinary approach. The treatment options available include medical treatment, chemotherapy, celiac plexus/ganglion neurolysis, radiotherapy, and endoscopic technique. This review discusses the medical and interventional options, leading to optimal pain management in patients with pancreatic cancer.
Drug Therapy
;
Humans
;
Pain Management
;
Pancreatic Neoplasms
;
Prognosis
;
Quality of Life
;
Radiotherapy
5.Relief of Cancer Pain in Patients with Pancreatic Cancer
The Korean Journal of Gastroenterology 2019;74(2):81-86
Pancreatic cancer is a dismal disease with a poor prognosis and is one of the most painful malignancies. Therefore, adequate pain control is essential to improving the patient's quality of life. Pain in pancreatic cancer has complex pathophysiologic mechanisms and different characteristics. The choice of pain management modalities should be individualized depending on the pain characteristics using a multidisciplinary approach. The treatment options available include medical treatment, chemotherapy, celiac plexus/ganglion neurolysis, radiotherapy, and endoscopic technique. This review discusses the medical and interventional options, leading to optimal pain management in patients with pancreatic cancer.
Drug Therapy
;
Humans
;
Pain Management
;
Pancreatic Neoplasms
;
Prognosis
;
Quality of Life
;
Radiotherapy
6.Preoperative Chemoradiation and Pancreaticoduodenectomy with Portal Vein Resection for Localized Advanced Pancreatic Cancer.
Yoon Seok CHAE ; Jin Sub CHOI ; Kyung Sik KIM ; Jin Sil SEONG ; Woo Jung LEE ; Byong Ro KIM
Yonsei Medical Journal 2003;44(3):551-556
Pancreatic adenocarcinoma is a common disease that is rarely cured. Surgical resection remains the only treatment modality that has a curative potential, although the majority of patients are unsuitable for resection at the time of diagnosis. Chemoradiation therapy prior to a pancreaticoduodenectomy ensures that a patient who undergoes a complete resection multimodality therapy, avoids a resection in patients who have a rapidly progressive disease, and allows radiation therapy to be given to well oxygenated cells before, surgical devasculation. This permits the chance of resection of an unresectable pancreatic cancer by downstaging. A patient with cytologic proof of localized adenocarcinoma of the pancreatic head received an intravenously chemoradiation (Taxol, 50 mg/m2 intravenously for 3 hours week on 5 cycles, of Gemcytabine 1000 mg/m2/day intravenously for 3 days week on 2 cycles, of 4500 cGy) with the intention of proceeding to a resection operation, restaging was performed by computed tomography, magnetic resonance imaging from 5 weeks every months due to ongoing decreasing of tumor size after the chemoradiation. At laparotomy, the patient didn't have suspected metastatic disease, the tumor size was 2 x 3 cm on the pancreas head and was infiltrating into the portal vein for about 3 cm length on right side. A pancreaticoduodenectomy along with a portal vein and superior mesenteric vein resection was done and then reconstruction of a vascular anastomosis by using the right side of the internal jugular vein. Perioperative complications didn't occur. In conclusion, preoperative chemoradiation of a localized advanced pancreatic tumor has no added risk to the operative complications and the prospects for resectability are enhanced.
Adenocarcinoma/diagnosis/drug therapy/radiotherapy/*surgery
;
Combined Modality Therapy
;
Human
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Pancreatic Neoplasms/diagnosis/drug therapy/radiotherapy/*surgery
;
*Pancreaticoduodenectomy
;
*Preoperative Care
7.Clinical Characteristics of Pulmonary Embolism with Underlying Malignancy.
Ji Eun LEE ; Hye Ryoun KIM ; Sang Min LEE ; Jae Joon YIM ; Chul Gyu YOO ; Young Whan KIM ; Sung Koo HAN ; Young Soo SHIM ; Seok Chul YANG
The Korean Journal of Internal Medicine 2010;25(1):66-70
BACKGROUND/AIMS: The risk of venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism (PE), increases in patients with cancer. Anticancer treatment is also associated with an increased risk for VTE. We conducted this study to investigate the clinical characteristics of patients with cancer and PE related to anticancer treatment in a tertiary care hospital in Korea. METHODS: We retrospectively reviewed the clinical data of patients with an underlying malignancy who were diagnosed with PE by chest computed tomography (CT) with or without lower extremity CT angiography between January 2006 and December 2007 at Seoul National University Hospital. RESULTS: Overall, 95 patients with malignancies among 168 with PE were analyzed. The median age was 64 years. The median time interval from the malignancy diagnosis to the PE diagnosis was 5.5 months. Lung cancer was the most common malignancy (23.0%), followed by pancreatobiliary cancer, stomach cancer, gynecological cancer, breast cancer, and hepatocellular carcinoma. Platinum-containing and pyrimidine analog-containing chemotherapeutic regimens were common. CONCLUSIONS: PE was diagnosed within 1 year after the cancer diagnosis in almost 70% of patients. Lung cancer was the most common underlying malignancy.
Adult
;
Aged
;
Aged, 80 and over
;
Angiography
;
Antineoplastic Agents/*therapeutic use
;
Biliary Tract Neoplasms/drug therapy/epidemiology/radiotherapy
;
Female
;
Humans
;
Lung Neoplasms/drug therapy/epidemiology/radiotherapy
;
Male
;
Middle Aged
;
*Neoplasms/drug therapy/epidemiology/radiotherapy
;
Pancreatic Neoplasms/drug therapy/epidemiology/radiotherapy
;
Pulmonary Embolism/*epidemiology/radiography
;
*Radiotherapy
;
Retrospective Studies
;
Risk Factors
;
Stomach Neoplasms/drug therapy/epidemiology/radiotherapy
;
Tomography, X-Ray Computed
8.Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer.
Hyeong Seok KIM ; Jin Young JANG ; Youngmin HAN ; Kyoung Bun LEE ; Ijin JOO ; Doo Ho LEE ; Jae Ri KIM ; Hongbeom KIM ; Wooil KWON ; Sun Whe KIM
Annals of Surgical Treatment and Research 2017;93(4):186-194
PURPOSE: Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors. METHODS: Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively. RESULTS: The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% vs. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% vs. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% vs. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months. CONCLUSION: Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.
Drug Therapy
;
Fluorouracil
;
Humans
;
Neoadjuvant Therapy*
;
Neoplasm Metastasis
;
Pancreatectomy
;
Pancreatic Neoplasms*
;
Prognosis
;
Prospective Studies
;
Radiotherapy
;
Recurrence
;
Retrospective Studies
;
Survival Rate
9.The Palliative Radiation Therapy in Malignant Extra-Hepatic Biliary Obstruction.
Chul Seung KAY ; Hong Suk JANG ; Sung Hwan KIM ; Mi Ryeong RYU ; Yeon Shil KIM ; Su Mi CHUNG ; Sei Chul YOON
The Journal of the Korean Society for Therapeutic Radiology and Oncology 1999;17(3):209-216
PURPOSE: To evaluate the effectiveness of external radiation therapy and the prognostic factors, we retrospectively analyzed therapeutic results of malignant extrahepatic biliary obstruction (EHBO). METHODS AND MATERIALS: We analyzed the results of the external radiation therapy in 59 patients of inoperable malignant EHBO who had been treated with more than 10 Gy of external radiation therapy from April 1984 to December 1996. There were 21 stomach cancer (35.6%), 12 pancreas cancer (20.3%), 15 extrahepatic biliary cancer (18.6%) and 11 another cancer (18.6%). Their pathologies were confirmed in 31 patients (52.5%). They divided into 27 adenocarcinoma and 4 nonadenocarcinoma. Their chief complaints were jaundice in 47 patients (79.7%) and abdominal pain in 15 patients (49.2%). Twelve patients had slightly increased bilirubin level in liver function test without jaundice. We treated twenty four patients (40.6%) with percutaneous transhepatic biliary drainage (PTBD) and 32 patients (54%) with systemic chemotherapy (CT). We performed external radiation therapy (ERT) upto 10.8~55.8 Gy (median 37.8 Gy) with palliative aim. RESULTS: Overall median survival duration was 7.80+/-1.15 months. The response rates of jaundice were 81.8% in PTBD group and 66.7% in non-PTBD group without statistical significance. The improving rate of jaundice was not significantly different in decreased ratio of total bilirubin level. But abdominal pain was more decreased in CT group than non-CT group (P<0.05). The significant prognostic factors were high performance status (Karnofski Performance Status >70), total radiation dose more than 35 Gy and good response of pain after therapy. There were increased in bacterial cholagitis in PTBD group and gastrointestinal complications in CT group. CONCLUSION: External radiotheapy could improve jaundice and abdominal pain in malignant EHBO patients. Overall survival duration was prolonged in patients with higher performance status and patients who had been treated with more than 35 Gy of total radiation dose. In the future, we expect not only better palliative role but also the prolongation of survival of using the ERT combined with other treatment method. But to achieve certain conclusion, we need futher study consisted with many kinds of treatment methods including new technologies in RT.
Abdominal Pain
;
Adenocarcinoma
;
Bilirubin
;
Drainage
;
Drug Therapy
;
Humans
;
Jaundice
;
Liver Function Tests
;
Pancreatic Neoplasms
;
Pathology
;
Radiotherapy
;
Retrospective Studies
;
Stomach Neoplasms
10.Survival and prognostic factors of unresectable pancreatic cancer.
Joo Kyung PARK ; Yong Bum YOON ; Yong Tae KIM ; Ji Kon RYU ; Jun Kyu LEE ; Won Jae YOON ; Sang Hyub LEE
Korean Journal of Medicine 2007;72(2):151-161
BACKGROUND: The prognosis of pancreatic cancer is very poor and it is generally unresectable when it is diagnosed. The aim of this study is to evaluate the prognostic significance of the clinical and laboratory variables, and the survival for unresectable pancreatic cancer patients. METHODS: We retrospectively collected 245 unresectable pancreatic cancer patients who were diagnosed and had their disease pathologically proved between Jan. 1999 to Dec. 2004. They underwent palliative interventions, including surgical bypass, palliative chemotherapy, palliative radiotherapy or supportive care. We also reviewed the medical records for the clinical and laboratory variables, and we investigated their survival data. RESULTS: The mean age of the patients was 60 years old (range: 28-87) and the median overall survival was 5.5 months. Age, performance status, tumor location, initial CA 19-9 level, AJCC staging and the treatment modality had prognostic significance on univariate analysis. On multivariate analysis, performance status, tumor location, AJCC staging and the treatment modality were independent prognostic factors. On the subgroup analysis, stage III patients who underwent concurrent chemoradiotherapy (CCRT, median OS 10.6 months) or chemotherapy alone (12.7) showed survival benefit over the best supportive care (6.1). Stage IV patients who underwent chemotherapy (6.3) alone showed survival benefit over the best supportive care (3.4). CONCLUSIONS: The performance status, AJCC staging, tumor location and the treatment modality were independent prognostic factors of unresectable pancreatic cancer. The patients who received chemotherapy or CCRT showed better survival than those who received the best supportive care group. Therefore, active treatment modality should be considered for unresectable pancreatic cancer.
Chemoradiotherapy
;
Drug Therapy
;
Humans
;
Medical Records
;
Middle Aged
;
Multivariate Analysis
;
Neoplasm Staging
;
Pancreatic Neoplasms*
;
Prognosis
;
Radiotherapy
;
Retrospective Studies